Free tool
FAERS Monitor: Seasonale
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021544 or its brand name (Seasonale, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.
Reports
419
Serious
256
61% of reports
Hospitalization
103
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea39
- vomiting30
- drug ineffective28
- headache22
- fatigue19
- pulmonary embolism19
- abdominal pain16
- dyspnoea16
- cholecystitis chronic14
- dizziness14
- abdominal pain upper13
- pruritus13
- rash13
- weight increased13
- chest pain12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 3 |
| 2006 | 22 |
| 2007 | 15 |
| 2008 | 3 |
| 2009 | 17 |
| 2010 | 16 |
| 2011 | 68 |
| 2012 | 40 |
| 2013 | 10 |
| 2014 | 17 |
| 2015 | 28 |
| 2016 | 46 |
| 2017 | 15 |
| 2018 | 21 |
| 2019 | 18 |
| 2020 | 12 |
| 2021 | 14 |
| 2022 | 16 |
| 2023 | 10 |
| 2024 | 9 |
| 2025 | 12 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,740 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cholecystitis chronicSignal | 14 | 105.2 | 62.8 | 1,340 |
| pulmonary embolismSignal | 19 | 10.0 | 6.5 | 146 |
| abdominal painSignal | 16 | 3.5 | 2.1 | 26 |
| chest painSignal | 12 | 3.3 | 1.9 | 17 |
| vomitingSignal | 30 | 3.2 | 2.3 | 44 |
| abdominal pain upperSignal | 13 | 3.2 | 1.9 | 17 |
| weight increasedSignal | 13 | 2.9 | 1.7 | 15 |
| nauseaSignal | 39 | 2.5 | 1.8 | 34 |
| headache | 22 | 1.8 | 1.2 | 7 |
| pruritus | 13 | 1.7 | 1.0 | 3 |
| rash | 13 | 1.5 | 0.9 | 2 |
| dyspnoea | 16 | 1.4 | 0.9 | 2 |
| dizziness | 14 | 1.4 | 0.8 | 1 |
| fatigue | 19 | 1.2 | 0.8 | 1 |
| drug ineffective | 28 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.